Physician profile
Holly Cockrum
NPI 1396788519
$4,948.17
in general payments reported to CMS, 2019-2025
29 companies · $809 in 2025
The $809 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $415 · 2021: $1,043 · 2022: $1,041 · 2023: $506 · 2024: $620 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.09 |
| Education | $233.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $845.39 | 2019-2025 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $683.35 | 2021-2025 | |
| Minerva Surgical, INC | $433.07 | 2021-2025 | |
| Pfizer INC. | $383.84 | 2019-2024 | |
| Astellas Pharma US INC | $383.52 | 2022-2025 | Veozah |
| Sumitomo Pharma America, INC. | $247.62 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $228.36 | 2019-2025 | Aptima, Thinprep 2000 Processor, Fluent Fluid Management System |
| Therapeuticsmd, INC. | $203.46 | 2019-2022 | |
| Myovant Sciences INC. | $195.97 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.12 | 2019-2025 | |
| Evofem Biosciences, INC. | $179.28 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $158.09 | 2019-2022 | |
| Organon LLC | $143.47 | 2021-2025 | Nexplanon |
| Biogen, INC. | $134.54 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $87.78 | 2023-2024 | Accrufer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $65.51 | 2019 | |
| Urovant Sciences INC | $58.97 | 2022 | |
| Avion Pharmaceuticals | $58.56 | 2021-2022 | |
| Amgen INC. | $42.38 | 2019-2020 | |
| Millicent US INC | $40.05 | 2024 | |
| Davol INC. | $34.12 | 2022 | |
| Allergan, INC. | $32.44 | 2019 | |
| Amag Pharmaceuticals, INC. | $23.91 | 2019 | |
| Ethicon US, LLC | $22.20 | 2020 | |
| Lupin INC. | $18.36 | 2020 | |
| Radius Health, INC. | $17.66 | 2020 | |
| Coloplast Corp | $14.57 | 2022 | |
| Currax Pharmaceuticals LLC | $14.09 | 2024 | Onzetra Xsail, Contrave |
| Merck Sharp & Dohme LLC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Cockrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.